Clinical Trials
6 trialsNCT02077192 2023-12-11
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Rigel Pharmaceuticals
Phase 3 Completed
NCT01957176 2022-12-30
A Rollover Study to Provide Continued Treatment With Eltrombopag
Novartis
Phase 4 Completed
NCT02076399 2019-02-12
FIT
Rigel Pharmaceuticals
Phase 3 Completed
NCT02076412 2019-01-25
FIT
Rigel Pharmaceuticals
Phase 3 Completed
NCT01444417 2017-02-09
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
Amgen
Phase 3 Completed
NCT00515203 2014-07-25
Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
Amgen
Phase 1/2 Completed